Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results

Authors :: G. Deplanque
Olivier Rixe
A. Goupil
B. Benettaib
E. Levy
Esteban Cvitkovic
M. Fabbro
Source :: Journal of Clinical Oncology. 22:5075-5075
Publication Year :: 2004
Publisher :: American Society of Clinical Oncology (ASCO), 2004.
Abstract: 5075 Background: Despite the introduction of paclitaxel/platinum combinations in first line treatment of AOC, a small proportion of patients fail to respond. This has been linked to genetic or epig...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Advanced ovarian cancer
business.industry
Oxaliplatin
First line treatment
chemistry.chemical_compound
Paclitaxel
chemistry
Internal medicine
medicine
First line chemotherapy
business
medicine.drug

Full Text Access

Tools